Members |
targetComponentId |
Reanastomosis of fallopian tube NEC |
Tubotubal anastomosis (procedure) |
Reanastomosis of fallopian tube NEC |
Tubotubal anastomosis (procedure) |
Reason not stated concept |
A component that is no longer current, useful, appropriate or acceptable. |
Reassurance given NOS |
Reassurance given (situation) |
Reassurance given NOS |
Reassurance given (situation) |
Reattached finger(s) complication |
Complication of reattached finger |
Recalcification, calcium hydroxide, temporary restoration, per tooth |
Insertion of calcium hydroxide dental cement into tooth |
Recent |
Recent |
Receptionist NOS |
Receptionist |
Receptionist NOS |
Receptionist |
Recession of lateral rectus muscle of eye NEC |
Lateral rectus recession |
Recession of lateral rectus muscle of eye NEC |
Lateral rectus recession |
Recession of medial rectus muscle of eye NEC |
Medial rectus recession (procedure) |
Recession of medial rectus muscle of eye NEC |
Medial rectus recession (procedure) |
Recessive congenital ichthyosiform erythroderma |
A rare, genetic, syndromic hair shaft abnormality disorder characterised by short, dry, sulphur-deficient, brittle hair usually associated with highly variable neuroectodermal manifestations, such as ichthyosis, photosensitivity, and intellectual disability. |
Recomb human follicle stim horm alpha 1200iu inj pdr+diluent |
Pituitary follicle stimulating hormone 1200 unit powder for solution for injection vial |
Recomb human follicle stim horm alpha 1200iu powder and solvent for injection solution |
Pituitary follicle stimulating hormone 1200 unit powder for solution for injection vial |
Recombinant alpha glucosidase 50mg powder for injection solution vial |
Product containing only alpha-glucosidase (medicinal product) |
Recombinant antihemophilic factor agent 1000 iu injection solution vial |
Antihemophilic factor agent only product |
Recombinant antihemophilic factor agent 1000iu powder for injection solution vial |
Antihemophilic factor agent only product |
Recombinant antihemophilic factor agent 1500 iu injection solution mL vial |
Antihemophilic factor agent only product |
Recombinant antihemophilic factor agent 1500iu powder for injection solution vial |
Antihemophilic factor agent only product |
Recombinant antihemophilic factor agent 2000 iu injection solution mL vial |
Antihemophilic factor agent only product |
Recombinant antihemophilic factor agent 2000iu powder for injection solution vial |
Antihemophilic factor agent only product |
Recombinant antihemophilic factor agent 250 iu injection solution mL vial |
Antihemophilic factor agent only product |
Recombinant antihemophilic factor agent 250iu powder for injection solution vial |
Product containing precisely octocog alfa 250 unit/1 vial powder for conventional release solution for injection (clinical drug) |
Recombinant antihemophilic factor agent 3000 iu injection solution mL vial |
Antihemophilic factor agent only product |
Recombinant antihemophilic factor agent 500 iu injection solution mL vial |
Antihemophilic factor agent only product |
Recombinant antihemophilic factor agent 500iu powder for injection solution vial |
Product containing precisely octocog alfa 500 unit/1 vial powder for conventional release solution for injection (clinical drug) |
Recombinant coagulation factor IX 1000iu powder and solvent for injection solution vial |
Product containing only nonacog alfa (medicinal product) |
Recombinant coagulation factor IX 1000iu powder for conventional release solution for injection vial |
Product containing only nonacog alfa (medicinal product) |
Recombinant coagulation factor IX 1000iu powder for injection solution vial |
Product containing precisely nonacog alfa 1000 unit/1 vial powder for conventional release solution for injection (clinical drug) |
Recombinant coagulation factor IX 250iu powder and solvent for injection solution vial |
Product containing only nonacog alfa (medicinal product) |
Recombinant coagulation factor IX 250iu powder for conventional release solution for injection vial |
Product containing only nonacog alfa (medicinal product) |
Recombinant coagulation factor IX 250iu powder for injection solution vial |
Product containing precisely nonacog alfa 250 unit/1 vial powder for conventional release solution for injection (clinical drug) |
Recombinant coagulation factor IX 500iu powder and solvent for injection solution vial |
Product containing only nonacog alfa (medicinal product) |
Recombinant coagulation factor IX 500iu powder for conventional release solution for injection vial |
Product containing only nonacog alfa (medicinal product) |
Recombinant coagulation factor IX 500iu powder for injection solution vial |
Product containing precisely nonacog alfa 500 unit/1 vial powder for conventional release solution for injection (clinical drug) |
Recombinant coagulation factor VIIa 120,000iu powder and solvent for injection solution vial |
Coagulation factor VIIa only product in parenteral dose form |
Recombinant coagulation factor VIIa 120,000iu powder for conventional release solution for injection vial |
Coagulation factor VIIa only product in parenteral dose form |
Recombinant coagulation factor VIIa 240,000iu powder and solvent for injection solution vial |
Coagulation factor VIIa only product in parenteral dose form |
Recombinant coagulation factor VIIa 240,000iu powder for conventional release solution for injection vial |
Coagulation factor VIIa only product in parenteral dose form |
Recombinant coagulation factor VIIa 60,000iu powder and solvent for injection solution vial |
Coagulation factor VIIa only product in parenteral dose form |
Recombinant coagulation factor VIIa 60,000iu powder for conventional release solution for injection vial |
Coagulation factor VIIa only product in parenteral dose form |
Recombinant human follicle stimulating hormone alfa 150iu/lutropin alfa 75iu powder and solvent for injection solution vial |
Product containing only follitropin alfa and lutropin alfa (medicinal product) |
Recombinant human follicle stimulating hormone alpha 1050iu injection (pdr for recon) |
Product containing only follitropin alfa (medicinal product) |
Recombinant human follicle stimulating hormone alpha 1050iu injection (pdr for recon)+diluent |
Product containing only follitropin alfa (medicinal product) |
Recombinant human follicle stimulating hormone alpha 150iu powder and solvent for injection solution ampule |
Follitropin alfa 300 unit/mL solution for injection |
Recombinant human follicle stimulating hormone alpha 37.5iu powder for conventional release solution for injection ampule |
Product containing precisely follitropin alfa 37.5 unit/1 milliliter conventional release solution for injection (clinical drug) |
Recombinant human follicle stimulating hormone alpha 450iu injection (pdr for recon) |
Product containing only follitropin alfa (medicinal product) |
Recombinant human follicle stimulating hormone alpha 450iu injection (pdr for recon)+diluent |
Product containing only follitropin alfa (medicinal product) |
Recombinant human follicle stimulating hormone alpha 75iu powder and solvent for injection solution ampule |
Product containing precisely follitropin alfa 75 unit/1 vial powder for conventional release solution for injection (clinical drug) |
Recombinant parathyroid hormone 100micrograms powder for injection solution cartridge and solvent |
Recombinant parathyroid hormone only product |
Recombinant thrombin 20000iu powder for conventional release cutaneous solution |
Product containing only thrombin in cutaneous dose form (medicinal product form) |
Recombinant thrombin 20000iu powder for topical solution + 20mL prefilled syringe diluent |
Product containing only thrombin in cutaneous dose form (medicinal product form) |
Recombinant thrombin 5000iu powder for conventional release cutaneous solution |
Product containing only thrombin in cutaneous dose form (medicinal product form) |
Recombinant thrombin 5000iu powder for topical solution + 5mL prefilled syringe diluent |
Product containing only thrombin in cutaneous dose form (medicinal product form) |
Reconnection and repair of ureter |
Anastomosis of ureter |
Reconstruction of breast using distant flap of skin NEC |
Reconstruction of breast using distant skin flap |
Reconstruction of jaw using pedicled bone flap |
Reconstruction of mandible using bone flap (procedure) |
Reconstruction of organ NOC |
A reparative construction that builds or rebuilds a structure that should normally be present. |
Reconstruction of urinary bladder |
Urinary bladder reconstruction |
Reconstruction using forehead flap graft |
Reconstruction using flap from forehead (procedure) |
Records/library clerk NOS |
Record keeping/library clerk |
Records/library clerk NOS |
Record keeping/library clerk |
Recreation manager NOS |
Recreation manager |
Recreation manager NOS |
Recreation manager |
Recreation/sport examination NOS |
History and physical examination, sports participation |
Recreation/sport examination NOS |
History and physical examination, sports participation |
Recreational therapy |
Recreational therapy |
Recreational therapy NOS |
Recreational therapy |
Recreational therapy NOS |
Recreational therapy |
Rectal prednisolone preparations allergy |
Allergy to prednisolone |
Rectally given laxatives |
Laxative (substance) |
Rectocele affecting obstetric care |
Rectocele in pregnancy, childbirth and puerperium (disorder) |
Rectus muscle sprain |
Strain of rectus abdominus muscle (disorder) |
Recurrent benign focal seizures of childhood |
A group of epilepsies characterized by age-dependent occurrence of drug responsive focal seizures in otherwise normal children. Seizures are focal motor or sensory with or without impaired awareness and may evolve to bilateral tonic-clonic seizures. Remission usually occurs by puberty. Development and cognition are typically normal. Neurological examination is normal. No significant structural lesions of the brain are present, and presumed genetic factors have an important role. The electroencephalogram (EEG) background activity is normal. Seizure semiology and EEG features are specific for each of the syndromes included in this group. |
Recurrent dislocation of other site, NEC |
Recurrent dislocation of joint |
Recurrent hernia |
Herniated structure (morphologic abnormality) |
Recurrent joint dislocation NOS |
Recurrent dislocation of joint |
Recurrent joint dislocation NOS |
Recurrent dislocation of joint |
Recurrent joint dislocation, of other specified site |
Recurrent dislocation of joint |
Recurrent joint dislocation, of other specified site |
Recurrent dislocation of joint |
Recurrent mouth ulcers |
Recurrent ulcer of mouth (disorder) |
Recurrent primary malignant neoplasm of left female breast |
Recurrent primary malignant neoplasm of left breast (disorder) |
Recurrent primary malignant neoplasm of right female breast |
Recurrent primary malignant neoplasm of right breast (disorder) |
Red blood cell count NOS |
Red blood cell count |
Red blood cell enzymes NOS |
Red blood cell enzyme test |
Red blood cell enzymes NOS |
Red blood cell enzyme test |
Red blood cell shape NOS |
Red blood cell shape |
Red blood cell shape NOS |
Red blood cell shape |
Red blood cell size NOS |
Red blood cell size - finding |
Red blood cell size NOS |
Red blood cell size determination |
Red blood cell test |
Haematology test |
Red color |
Red color (qualifier value) |
Red color |
Red color (qualifier value) |
Red eye |
Red eye |
Reductase |
Reductase |
Reduction of atraumatic hip dislocation with general anesthesia |
Administration of anesthesia (procedure) |
Reduction of closed talotarsal joint dislocation with anesthesia |
Administration of anesthesia (procedure) |
Reduction of closed tarsometatarsal joint dislocation with anesthesia |
Administration of anesthesia (procedure) |